Mazdutide — EU research guide.

What is Mazdutide?

Mazdutide is a once-weekly injectable dual agonist that simultaneously activates GLP-1R (for satiety and insulin secretion) and GCGR (for energy expenditure and hepatic fat reduction). Developed primarily in China, it is in late-stage clinical trials and not yet approved by EMA or FDA.

What does the research show?

Phase 3 data in Chinese populations showed ~15% body weight reduction at 48 weeks with 9mg weekly dosing, alongside significant improvements in glycaemic markers. The GCGR component adds thermogenic and hepatoprotective activity not seen with GLP-1-only agonists. As of mid-2026 no EU or US approval exists.

EU legal status

Mazdutide is not approved in the EU. It is available from research vendors as a laboratory compound. No clinical use is sanctioned outside of authorized trials.